In Stockhead: Racura Oncology races ahead in FY24 with key milestones

Racura Oncology is pleased to release the FY24 annual report. Key highlights include:

• Racura Oncology hails significant FY24 with several key milestones achieved
• First batch of (cGMP) manufacturing and toxicology study successfully completed for Racura’s new bisantrene formulation RC220
• Preclinical work in the past year has demonstrated the drug’s potent cancer killing effect

Read the full report via this link.